Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Review of Pharmacoeconomics and Outcomes Research is Scopus-indexed (Q2, CiteScore 3.4), ABDC C, WoS SCIE/SSCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor & Francis Online.
Checked against the index lists dated .
ISSN 1473-7167Verify ISSN ↗1744-8379Verify ISSN ↗
Publisher: Taylor & Francis Online
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Health Policy | 142 / 330 | 57th | Q2 |
| Pharmacology (medical) | 154 / 278 | 44th | Q3 |
Not listed in: DOAJ, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q2, CiteScore 3.4.
Expert Review of Pharmacoeconomics and Outcomes Research is Q2 in Health Policy (rank 142 of 330) and Q3 in Pharmacology (medical) (rank 154 of 278), by CiteScore 2025.
Expert Review of Pharmacoeconomics and Outcomes Research is indexed in the Science Citation Index Expanded and Social Sciences Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.4, which places it in quartile Q2 at the 57th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.511, quartile Q3, with an H-index of 69.
Expert Review of Pharmacoeconomics and Outcomes Research is published by Taylor & Francis Online. Its print ISSN is 1473-7167 and its online ISSN is 1744-8379.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded and Social Sciences Citation Index.
It is rated C in the ABDC Journal Quality List 2025 under Applied economics.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Expert Review of Pharmacoeconomics and Outcomes Research has an h-index of 81 and a 2-year mean of 1.9 citations per paper (OpenAlex). Its Scopus CiteScore is 3.4, quartile Q2. On 2-year citations it ranks #123 of 327 Scopus journals in Health Policy.
Expert Review of Pharmacoeconomics and Outcomes Research published 129 papers in 2025; its busiest recent year was 2023 with 131. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (21.3%), China (16.5%) and Iran (5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.